HKSE:02500 (China)
Â
Class H
HK$
1.1
-0.030 (-2.65%)
Aug 3
Business Description
Venus Medtech (Hangzhou) Inc
ISIN : CNE100003PJ8
Share Class Description:
HKSE:02500: Class HTotal Employee Number:
560Compare
Compare
Traded in other countries / regions
02500.Hong KongVMTHF.USA Index Membership
Hong Kong Stock Connect IPO Date
2019-12-10Description
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.25 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.22 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.05 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.3 | |||||
3-Year EBITDA Growth Rate | 34.1 | |||||
3-Year EPS without NRI Growth Rate | 26.3 | |||||
3-Year FCF Growth Rate | 28.7 | |||||
3-Year Book Growth Rate | -21.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.55 | |||||
9-Day RSI | 35.88 | |||||
14-Day RSI | 38.82 | |||||
3-1 Month Momentum % | -5.46 | |||||
6-1 Month Momentum % | -39.3 | |||||
12-1 Month Momentum % | -49.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.77 | |||||
Quick Ratio | 2.37 | |||||
Cash Ratio | 1.1 | |||||
Days Inventory | 379.53 | |||||
Days Sales Outstanding | 170.53 | |||||
Days Payable | 86.76 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.02 | |||||
Operating Margin % | -106.93 | |||||
Net Margin % | -133.29 | |||||
EBITDA Margin % | -94.77 | |||||
FCF Margin % | -108.54 | |||||
OCF Margin % | -105.04 | |||||
ROE % | -20.5 | |||||
ROA % | -13.93 | |||||
ROIC % | -13.55 | |||||
3-Year ROIIC % | -25.97 | |||||
ROC (Joel Greenblatt) % | -91.47 | |||||
ROCE % | -14.91 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 91.67 | |||||
PS Ratio | 1.4 | |||||
PB Ratio | 0.25 | |||||
Price-to-Tangible-Book | 1.26 | |||||
EV-to-EBIT | -0.63 | |||||
EV-to-Forward-EBIT | 12.26 | |||||
EV-to-EBITDA | -0.84 | |||||
EV-to-Forward-EBITDA | 10.07 | |||||
EV-to-Revenue | 0.8 | |||||
EV-to-Forward-Revenue | 1.87 | |||||
EV-to-FCF | -0.74 | |||||
Price-to-GF-Value | 0.33 | |||||
Earnings Yield (Greenblatt) % | -158.73 | |||||
FCF Yield % | -75.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Venus Medtech (Hangzhou) Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 336.731 | ||
| EPS (TTM) (HK$) | -1.024 | ||
| Beta | 0.7151 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.71 | ||
| Volatility % | 53.69 | ||
| 14-Day RSI | 38.82 | ||
| 14-Day ATR (HK$) | 0.123316 | ||
| 20-Day SMA (HK$) | 1.2595 | ||
| 12-1 Month Momentum % | -49.56 | ||
| 52-Week Range (HK$) | 1.01 - 5.47 | ||
| Shares Outstanding (Mil) | 441.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Venus Medtech (Hangzhou) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Venus Medtech (Hangzhou) Inc Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Venus Medtech (Hangzhou) Inc Frequently Asked Questions
What is Venus Medtech (Hangzhou) Inc(HKSE:02500)'s stock price today?
The current price of HKSE:02500 is HK$1.10. The 52 week high of HKSE:02500 is HK$5.47 and 52 week low is HK$1.01.
When is next earnings date of Venus Medtech (Hangzhou) Inc(HKSE:02500)?
The next earnings date of Venus Medtech (Hangzhou) Inc(HKSE:02500) is .
Does Venus Medtech (Hangzhou) Inc(HKSE:02500) pay dividends? If so, how much?
Venus Medtech (Hangzhou) Inc(HKSE:02500) does not pay dividend.
Press Release
Articles on Venus Medtech (Hangzhou) Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers